Malta, 04 April 2006

MA Circular No. P07/2006

Dear Healthcare Professional,

Re: Precautions on the use of Elidel® (pimecrolimus) and Protopic®/Protopy® (tacrolimus)

Following the recent press release on the precautions of **Elidel® (pimecrolimus) and Protopic®/Protopy® (tacrolimus)** by the European Medicines Agency (EMEA), the Medicines Authority is providing **the press release** and **Q & A document** issued by the EMEA for your perusal.

Precribers are reminded that the EMEA's safety review of Elidel® was carried out based on its indication in patients over 2 years of age. Elidel® is currently being assessed by the Medicines Authority as part of the PMA-MA process and the outcome of this safety review will be taken into consideration in the overall scientific assessment of this medicinal product.

Medicines Authority
198, Rue D'Argens, Gzira, GZR 03 – Malta.
Tel. (+356) 23439000 Fax. (+356) 23439161 www.medicinesauthority.gov.mt
VAT No. 1715 7330